Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Operating Expenses data on file, last reported at $30.9 million in Q4 2025.

• On a quarterly basis, Operating Expenses fell 38.19% year-over-year to $30.9 million in Q4 2025; TTM through Dec 2025 was $136.3 million, a 58.89% decrease from a year earlier, with the FY2025 full-year figure at $136.3 million, down 58.89% from the prior year.
• Operating Expenses for Q4 2025 stood at $30.9 million, down from $33.8 million in the prior quarter.
• Over the last five years, Operating Expenses for INBX reached as high as $161.0 million in Q2 2024 and fell as low as $28.7 million in Q2 2025.
• Historically, Operating Expenses has averaged $58.7 million across 3 years, with a median of $45.9 million in 2023.
• Across the five-year window, Operating Expenses jumped 289.18% in 2024 and sank 82.18% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $89.9 million in 2023, then slumped by 44.37% to $50.0 million in 2024, then slumped by 38.19% to $30.9 million in 2025.
• Per Business Quant data, the three most recent Operating Expenses figures were $30.9 million in Q4 2025, $33.8 million in Q3 2025, and $28.7 million in Q2 2025.